Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class

Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated significant cardiovascular benefits in clinical trial. While their role in reducing heart failure hospitalizations and cardiovascular mortality is well established, the precise mechanisms underlying their direct cardiac...

Full description

Saved in:
Bibliographic Details
Main Authors: Steven Hopkins M.D., Faiz Baqai M.D., Saivaroon Gajagowni M.D., Gavin Hickey M.D.
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Journal of Cardiovascular Pharmacology and Therapeutics
Online Access:https://doi.org/10.1177/10742484251323428
Tags: Add Tag
No Tags, Be the first to tag this record!